Oculis Reports Q3 2025 Financial Results and Shares Company Updates

ZUG, Switzerland—Oculis Holding AG (Nasdaq: OCS / XICE: OCS), a global biopharmaceutical company focused on innovations to address unmet medical needs in ophthalmology and neuro-ophthalmology, announced results for the third quarter ended September 30, 2025, and provided an overview of the company’s progress. As of September 30, 2025, Oculis reporting holding cash, cash equivalents and short-term investments of $182.2 million. Following its October capital raise, the company’s cash, cash equivalents and short-term investments was close to $300 million, the company noted, extending its cash runway into 2029.